Contributors:
Kaycee Sink, MD, MAS (Chief Medical Officer)
Svenja Wacker, PhD (Neuropsychology Science Director)
The Free and Cued Selective Reminding Test (FCSRT) is a standardized, widely validated cognitive measure commonly used in preclinical Alzheimer’s disease (AD) trials. Developed in 1987 by Grober and Buschke, the test evaluates episodic memory through three phases: Learning/Encoding, Immediate Recall (Free and Cued), and Delayed Recall (Free and Cued). A performance-based outcome administered by trained clinicians or raters, the FCSRT offers meaningful insight into learning as well as spontaneous and cued memory recall, reflecting key encoding, storage, and retrieval processes.
By controlling learning conditions, the FCSRT reduces the impact of normal age-related retrieval difficulties while offering limited benefit for individuals with dementia, improving its ability to differentiate dementia from healthy aging compared with less structured memory tests.
Informed by decades of experience in guiding global AD trials, Cogstate scientific leaders explore the advantages, challenges, and considerations of effective use of the FCSRT as a clinical trial endpoint.
Advantages
The FCSRT is particularly well suited for detecting and characterizing memory impairment in Alzheimer’s disease research. Given its structure, the scale provides a comprehensive assessment of memory impairment because it evaluates multiple aspects of memory. It also lends itself well to remote administration with some modifications.
“In preclinical and early Alzheimer’s disease trials, the FCSRT can be effective as an endpoint because of its high sensitivity and specificity in detecting early cognitive changes,” says Dr. Svenja Wacker, Neuropsychology Science Director. “In addition, results from the assessment can have a predictive value for disease progression.”
Challenges and Considerations
Although the FCSRT has strengths as an endpoint, special considerations must be made when implementing the scale in an AD trial.
The FCSRT can be susceptible to practice effects and repeated administration of the assessment can inflate scores due to familiarity with the test procedure and materials. This reality can limit the test sensitivity to detecting real changes in cognition over time.
Administration of FCSRT is time consuming, complex, and requires a high level of clinical skills to administer correctly, which may increase costs and limit practicality for large scale clinical trials.
The concepts and pictures presented as part of the FCSRT assessment may be more familiar to individuals from certain cultural contexts than others, resulting in introduction of cultural bias and inaccurate measure of cognitive abilities for some cultural groups. In many trials with global footprints, this scale has been used successfully after careful translation and localization efforts. When interpreting outcome data from different geographic regions, the possible impact of residual bias should be considered.
Given the complexity of this scale and the high potential for rater error in administering this instrument, comprehensive rater training and stringent quality control need to be deployed to ensure mastery in administering and scoring this test.
- Tailored rater training equips clinicians with targeted, role-specific instruction and deliberate practice opportunities, reducing variability and minimizing common administration and scoring errors.
- Strategic central monitoring enables ongoing oversight of rater performance, allowing for early detection of drift, protocol deviations, or emerging trends that could compromise data integrity.
- Expert central rating adds an additional layer of quality control, ensuring consistent application of scoring criteria and clinical judgment across sites.
- Guidance from clinicians who are familiar with the scale and also familiar with the geographic regions where it will be leveraged can ensure the pictures are contextualized appropriately for accurate data collection in all study regions.
- Finally, seamless integration with leading eCOA platforms streamlines administration, automates workflows, and reduces operational friction, helping sites focus on accurate assessment delivery.
Wrapping Up
The Free and Cued Selective Reminding Test remains an informative endpoint for evaluating episodic memory in preclinical and early Alzheimer’s disease trials. Its structured approach to learning and recall provides insight into the mechanisms underlying memory impairment and supports early detection of disease-related change.
Thoughtful implementation, including robust rater training, careful management of practice effects, and culturally appropriate adaptation, is essential to realizing its full potential. When applied with these considerations in mind, the FCSRT can offer meaningful, high-quality data that advances both scientific understanding and the development of novel Alzheimer’s disease therapies.
- This blog is part of a series exploring the individual scales reviewed in our Alzheimer’s Disease Clinical Trial Endpoint Guide. Access the full guide here.
- Interested in learning more? We are happy to discuss endpoint selection with your team in more depth. Contact us today.
Sources
